

PROGRAMMA

Thursday 19th April 2012 Morning Sessions

OPENING

07.50-08.20 Registration

ROOM A

Plenary Session

CONGRESS OPENING

08.20-08.40 Welcome: **A. Frega, C. Gentili**

08.40-09-00 **Opening Lecture** A doctor for women in ancient Rome. **L.R. Angeletti**

ROOM A

Cervical Cancer The Global Picture

09.00-10.50 Infection & Cervical Cancer

Chairs: A. Lenzi, J. Paavonen

HPV infection and cervical cancer around the world.

F. Bray

Natural history of HPV infection in teenage and adult women. **A.B. Moscicki**

Does natural immunity prevent repeat infection, CIN, cervical cancer? **J. Dillner**

Oral contraceptives, hormonal replacement therapy and cervical cancer. **A. Szarewski**

HPV infection in men; can we really stop cervical cancer without addressing this? **J. Dillner**

Questions

10.50-11.20 Break

11.20-13.20 Cervical Cancer Prevention on Five Continents

Chairs: P. Giorgi Rossi, C. Meijer

Variation in cervical cancer rates around the world; what are the causes? **F. Bray**

Optimal cervical cancer prevention in high resource countries. **P. Walker**

Cervical cancer prevention in low resource countries; the options and the data. **V. Tsu**

Cervical cancer prevention in Eastern Europe. **P. Davies**

Questions

Debate: HPV vaccination is the only realistic option for cervical cancer prevention in low resource countries.

R. Sankaranarayanan - A. Szarewski

13.40-14.40 Lunch

14.20-14.50 Satellite Symposia

ROOM B

09.00-10.50 Free Communications

Chairs: A. Lukic

10.50-11.20 Break

11.20-13.40 Free Communications

Chairs: A. Venuti

13.40-14.50 Lunch

Thursday 19th April 2012 Afternoon Sessions

ROOM A

Clinical Session

HPV Vaccination Session

14.50-16.40 HPV Vaccination I

Chairs: R. De Vincenzo, J. Dillner

HPV vaccine efficacy in adolescents and in sexually active women. **J. Paavonen**

HPV vaccine cross-protection. What is the additional clinical benefit? **A.B. Moscicki**

Duration of protection. What happens when immunity wanes? **A.B. Moscicki**

HPV vaccines; do we really need 3 doses? **R. Sankaranarayanan**

Prophylactic HPV vaccines: what is in the pipeline? **J. Dillner**

Questions

16.40-17.20 Break & Free Communications

17.20-19.10 HPV Vaccination II

Chairs: A. Lukic, J. Paavonen

HPV vaccination policies and practices across Europe. **J. Dillner**



Vaccination coverage. What are the data, what are the issues? **J. Paavonen**

Therapeutic vaccines for cervical cancer; mirage or reality? **J. Dillner**

HPV vaccination adverse events; what is the truth? **A. Perino**

Questions

Debate: should we be promoting HPV vaccination to sexually active adults?

A. Szarewski - J. Paavonen

ROOM B

Cytopathology Session

14.50-16.40 Improving the Predictive Value of Cytopathology I

Chairs: M. Bibbo, A. Venuti

A review of cervical carcinogenesis and the biomarkers that could improve the identification of progressive cervical disease.

M. Tommasino

HPV DNA typing; is there a role for it in cervical cancer screening? **C. Meijer**

HPV RNA detection: an overview of the evidence.

D. French

Combining HPV testing and molecular markers; what gives the best PPV? **L. Dillner**

ASC-US, ASC-H what news since Bethesda 2001?

C. Bergeron

Questions

16.40-17.20 Break & Free Communications

17.20-19.10 Improving the Predictive Value of

Cytopathology II

Chairs: C. Bergeron, A. Vocaturo

Diagnostic dilemmas in cervical cytopathology.

M. Bibbo

Molecular markers; what do they add to clinical decision making? **W. Prendiville**

Using biomarkers to improve reproducibility and PPV of cytopathology. **A. Ferenczy**

Questions/Answers

Debate: enough of the molecular marker theory; do we have enough data for clinical recommendations? **C. Meijer - P. Walker**

Friday 20th April 2012 Morning Sessions

ROOM A

Plenary Session

Cervical Cancer Screening "What a long, strange trip it's been."

08.30-10.20 Screening in the 21st Century

Chairs: P. Davies, M.C. Tufi

The future of cervical cancer prevention.

M. Bibbo

New screening tests; looking beyond HPV testing. **L. Dillner**

Cervical screening in North America and Europe.

C. Meijer - A. Ferenczy

Self-sampling, a new way to improve screening coverage? **F. Carozzi**

Questions

10.20-10.50 Break

10.50-13.00 Clinicians and Pathologists:

Two Sides

of the Same Coin or Two Different Coins?

Chairs: S. Dexeus, A. Vecchione

Do we need cervical cytology at all anymore? The entirely molecular model.

Alex Ferenczy - C. Bergeron

What do you do with the HPV positive, cytology negative woman? **C. Meijer - K.U. Petry**

The evolution of cytology classification; who does this help: the pathologist, clinician or patient?


S. Dexeus - L. Turnbull

ASCUS, a diagnosis or just passing the buck? **M. Desai - W. Prendiville**

HSIL but clinically normal, who is wrong? **C. Bergeron - K.U. Petry**

Choosing the optimum treatment, what does it take? **A. Herbert - P. Walker**

Questions



13.10-13.30 Satellite Symposia
13.40-14.50 Lunch & Satellite Symposia

ROOM B

08.30-10.00 Free Communications

Chairs: D. French – R. Zarcone

10.00-10.20 Satellite Symposia

10.20-10.50 Break

10.50-13.00 Education and
Communication for Cervical Cancer
Prevention

Chairs: R. De Vincenzo, A.B. Moscicki

Awareness of HPV and cervical cancer in Europe; where are we now? **Y. Panayotova**
Awareness and acceptance of HPV vaccination in low resource settings. **V. Tsu**

How to sell cancer prevention in Europe. **P. Davies**

Why do some populations reject HPV vaccination? **Y. Panayotova**
HPV vaccination; will it affect women's views of screening? **P. Davies**

Raising awareness about HPV vaccination; what are the key issues for the public? **A. Szarewski**

Questions

13.00-13.40 Free Communications

13.40-14.50 Lunch

Friday 20th April 2012 Afternoon Sessions

ROOM A

Clinical Session

14.50-16.00 Disease Management

Chairs: M. Marchionni, W. Prendiville

Assessing risk in clinical practice. What are the key determinants? **P. Walker**

Special cases: managing cervical disease in menopausal women. **K.U. Petry**

Questions

Debate: Should cervical screening be limited only to women aged 25 or older?

S. Dexeus - A.B. Moscicki

16.00-17.10 Practical Issues in Treatment
of

Cervical Disease

Chairs: S. Dexeus, F. Sesti

Can treatment of CIN result in immune response that result in regression and protection? **A.B. Moscicki**

Adverse pregnancy outcomes after treatment for CIN, defining the limits of safety.

W. Prendiville

In the treatment of CIN, cancer prevention must be the main concern: two cultures, one message.

K.U. Petry - W. Prendiville

Questions

17.10-17.50 Break

17.50-19.00 Genital Warts

Chairs: G. Petricone K.U. Petry

HPV vaccination and the prevention of genital warts. So now we vaccinate the boys, right?

A. Ferenczy

Current trends in the treatment of genital warts.

C. Penna

Anal colposcopy: the tricks of the trade. **A. Ferenczy**

Questions

ROOM B

Cytopathology Session

14.50-15.40 Cervical Cytology in the Era of HPV Vaccination

Chairs: M.R. Giovagnoli, A. Herbert

HPV vaccination coverage that is too low to affect cervical cancer rates but high enough to reduce the performance of cytology. What do we do? **C. Bergeron**

Preparing for changes in cervical cytology.

What needs to be done? **M. Desai**

Questions

15.40-17.10 Liquid Based Cytology

Chairs: C. Bergeron, O. Nappi



LBC, what are the benefits and drawbacks? **L. Turnbull**

LBC, comparing the methods. **M. Desai**

Is LBC no more sensitive than the Pap in all settings?

A. Herbert

Why I prefer the traditional Pap smear.

L. Di Bonito

Questions

17.10-17.50 Break

17.50 -19.00 The New Scenarios in the
Lab

Chairs: G.L. Taddel, L. Turnbull

Using molecular markers for quality control in cytopathology. **M. Bibbo**

The equivocal Pap test: its past, present and future. **A. Herbert**

The role of computer assisted cytology in the era of HPV testing. **M. Bibbo**

Questions

Saturday 21st April 2012 Morning Sessions

Training Courses

ROOM A

08.30-09.45 Colposcopy Training Course
Part I

Chairs: P. Stentella

The main infections of lower genital tract.

G. Miniello

New devices in colposcopy. **S. Votano**

Colposcopy of the transformation zone in different stages of life. **F. Boselli**

Grading colposcopic features. **A. Biamonti**

Colposcopy and the management of CIN

during pregnancy. **P. Scirpa**

09.45-10.00 Break

10.00-11.45 Colposcopy Training Course
Part II

Chairs: S. Costa

Office procedures: what you can do and what you can't: the guidelines for Europe. **C. Zanardi**

From abnormal cytology to optimum

treatment. **K.U. Petry**

The AGC Pap; management and follow-up.

S. Dexeus

Management of recurrent CIN. **M. Barbero**

The confessions of an "expert": two errors that I could have avoided.

-S. Dexeus - G. Miniello - U.K. Petry

11.50-12.00 Break

ROOM B

08.30-09.45 Cytopathology Training
Course Part I

Chairs: G.F. Zannoni

Cervical cancer screening errors and reporting.

L. Turnbull

Understanding the abnormal in cervical cytopathology. **P. Dalla Palma**

Small cells and pale dyskaryosis: a tricky condition also for experts. **L. Turnbull**

Atrophic vaginitis versus invasive squamous cell carcinoma on ThinPrep cytology: can the background be reliably distinguished? **M. Desai**

Iatrogenic effects in cervical cytology. **P. Dalla Palma**

10.00-11.45 Cytopathology Training
Course Part II

Chairs: P. Dalla Palma

Benign glandular changes: differentiation from squamous and glandular dysplasia. **L. Turnbull**

Adenocarcinoma, AIS and AGC: an overview



L. Di Bonito

Confessions of the "experts": two errors that I could have avoided. **L. Di Bonito - A. Herbert - M. Desai**

Questions

11.50-12.00 Break

ROOM A



Plenary Session

12.00-12.20 ECM and CME Quiz

12.20-12.50 Presentation and award ceremony for the two best presentations and posters.

Chairs: A. Frega, C. Gentili

12.50. -13.10 Concluding Lecture

The elimination of cervical cancer; we have the tools but how do we achieve the goal? **P. Davies**

Davies

13.10 Conclusions and Meeting Close